TRUSELTIQ Drug Insight

“TRUSELTIQ Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about TRUSELTIQ for Cholangiocarcinoma (CCA) in the seven major markets. A detailed picture of the TRUSELTIQ for Cholangiocarcinoma  in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019–2032 is provided in this report along with a detailed description of the TRUSELTIQ for Cholangiocarcinoma. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TRUSELTIQ market forecast, analysis for Cholangiocarcinoma in the 7MM descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Cholangiocarcinoma.

Drug Summary

TRUSELTIQ (infigratinib) is an orally administered FGFR1-3 tyrosine kinase inhibitor in development for the treatment of patients with FGFR-driven diseases, including cholangiocarcinoma (bile duct cancer), urothelial carcinoma (bladder cancer), and achondroplasia. Infigratinib sparingly inhibits FGFR4; patients may tolerate it better than pan-FGFR1-4 inhibitors. QED Therapeutics holds worldwide rights to infigratinib to evaluate its safety and efficacy for multiple FGFR-driven diseases.

The company is also evaluating the product in a phase III clinical study for first-line therapy for cholangiocarcinoma (bile duct cancer) and in a phase II as second-line therapy for cholangiocarcinoma (bile duct cancer). It presented data on infigratinib in cholangiocarcinoma and urothelial carcinoma at the American Society of Clinical Oncology 2020 virtual scientific program.

• Dosage and administration

The recommended dosage of TRUSELTIQ is 125 mg (one 100 mg capsule and one 25 mg capsule) taken orally once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles. Continue treatment until disease progression or unacceptable toxicity

If a dose of TRUSELTIQ is missed by ≥4 hours or if vomiting occurs, instruct patients to resume the regular daily dose schedule for TRUSELTIQ the next day.

• Mechanism of Action

Infigratinib is a small-molecule kinase inhibitor of FGFR with IC50 values of 1.1, 1, 2, and 61 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. The major human metabolites of infigratinib, BHS697 and CQM157, have similar in vitro binding affinities for FGFR1, FGFR2, and FGFR3 compared to infigratinib. Infigratinib inhibited FGFR signaling and decreased cell proliferation in cancer cell lines with activating FGFR amplifications, mutations, or fusions. Constitutive FGFR signaling can support the proliferation and survival of malignant cells. Infigratinib had anti-tumor activity in mouse and rat xenograft models of human tumors with activating FGFR2 or FGFR3 alterations, including two patient-derived xenograft models of cholangiocarcinoma that expressed FGFR2-TTC28 or FGFR2-TRA2B fusions. Infigratinib demonstrated brain-to-plasma concentration ratios (based on AUC0-inf) of 0.682 in rats after a single oral dose.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the TRUSELTIQ description, mechanism of action, dosage and administration, research and development activities in Cholangiocarcinoma.
• Elaborated details on TRUSELTIQ regulatory milestones and other development activities have been provided in this report.
• The report also highlights the TRUSELTIQ research and development activity in Cholangiocarcinoma in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around TRUSELTIQ.
• The report contains forecasted sales of TRUSELTIQ for Cholangiocarcinoma till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Cholangiocarcinoma.
• The report also features the SWOT analysis with analyst views for TRUSELTIQ in Cholangiocarcinoma.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TRUSELTIQ Analytical Perspective by DelveInsight

• In-depth TRUSELTIQ Market Assessment

This report provides a detailed market assessment of TRUSELTIQ in Cholangiocarcinoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• TRUSELTIQ Clinical Assessment

The report provides the clinical trials information of TRUSELTIQ in Cholangiocarcinoma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Cholangiocarcinoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TRUSELTIQ dominance.
• Other emerging products for Cholangiocarcinoma are expected to give tough market competition to TRUSELTIQ and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TRUSELTIQ in Cholangiocarcinoma.
• Our in-depth analysis of the forecasted sales data from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TRUSELTIQ in Cholangiocarcinoma.

Key Questions

• What is the product type, route of administration and mechanism of action of TRUSELTIQ?
• What is the clinical trial status of the study related to TRUSELTIQ in Cholangiocarcinoma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TRUSELTIQ development?
• What are the key designations that have been granted to TRUSELTIQ for Cholangiocarcinoma?
• What is the forecasted market scenario of TRUSELTIQ for Cholangiocarcinoma?
• What are the forecasted sales of TRUSELTIQ in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available in Cholangiocarcinoma and how are they giving competition to TRUSELTIQ for Cholangiocarcinoma?
• Which are the late-stage emerging therapies under development for the treatment of Cholangiocarcinoma?